Page 20«..10..19202122..3040..»

Category : Nanomedicine

Nanomedicine Market to Witness Increasing Growth $261063 Million at CAGR of 12.6% In 2023 – PharmiWeb.com

UPDATE AVAILABLE ON-DEMAND

The globalnanomedicine marketwas valued at $111,912 million in 2016, and is projected to reach $261,063 million by 2023, growing at a CAGR of 12.6% from 2017 to 2023. The drug delivery segment accounted for nearly two-fifths share of the global market in 2016.

Nanomedicine is an application of nanotechnology that deals in the prevention & treatment of diseases in humans. This technology uses submicrometer-sized particles for diagnosis, treatment, and prevention of diseases. Nanomedicines are advantageous over generic drugs in several aspects such as, to reduce renal excretion, improve the ability of drugs to accumulate at pathological sites, and enhance the therapeutic index of drugs. Thus, nanomedicine is used in a wide range of applications that include aerospace materials, cosmetics, and medicine.

Download Free Report Sample @https://www.alliedmarketresearch.com/request-sample/2021

The global market is driven by increase in the development of nanotechnology-based drugs, advantages of nanomedicine in various healthcare applications, and growth in need of therapies with fewer side effects. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth. In addition, growth of healthcare facilities in emerging economies is anticipated to provide numerous opportunities for the market growth.

The vaccines segment is expected to register a significant CAGR of 13.2% throughout the forecast period. The treatment segment accounted for about fourth-sevenths share in the global market in 2016, accounting for the highest share during the forecast period. This is due to the high demand for therapeutics among patient and rise in the incidence of chronic diseases.

The neurological diseases segment is expected to grow at the highest CAGR of 13.9% during the forecast period, owing to high demand for brain monitoring & treatment devices and drugs. The oncological diseases segment accounted for the highest revenue in 2016, with one-third share of the global market, and is expected to maintain its dominance throughout the forecast period.

Get a purchase Enquiry @https://www.alliedmarketresearch.com/purchase-enquiry/2021

In 2016, Asia-Pacific and LAMEA collectively accounted for about one-fourth share of the global market, and is expected to continue this trend due to increased adoption of nanomedicines, especially in China, India, and the other developing economies. In addition, rise in investments by key players in the field of nanomedicines is key driving factor of the Asia-Pacific market.

The Major Key Players Are:

Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.

The other prominent players Are:

Celgene Corporation, UCB (Union Chimique Belge) S.A., AMAG Pharmaceuticals, Nanospectra Biosciences, Inc., Arrowhead Pharmaceuticals, Inc., Leadiant Biosciences, Inc., Epeius Biotechnologies Corporation, Gilead, and Cytimmune Sciences, Inc.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying:https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information:https://www.alliedmarketresearch.com/library-access

Similar Reports:

India Disposable Gloves Market

ASEAN Blood Pressure Monitoring Devices Market

North America Medical Tourism Market

Companion Diagnostic Market

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies clients insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa5933 NE Win Sivers Drive#205, Portland, OR 97220United StatesUSA/Canada (Toll Free):+1-800-792-5285, +1-503-894-6022, +1-503-446-1141UK:+44-845-528-1300Hong Kong:+852-301-84916India (Pune):+91-20-66346060Fax:+1(855)550-5975help@alliedmarketresearch.comWeb:https://www.alliedmarketresearch.comMarket Pulse:https://blog.alliedmarketresearch.comFollow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at contact@wiredrelease.com.

Go here to read the rest:
Nanomedicine Market to Witness Increasing Growth $261063 Million at CAGR of 12.6% In 2023 - PharmiWeb.com

Recommendation and review posted by Alexandra Lee Anderson

3D printing and nanomedicine combined to combat HIV – TheRecord.com

WATERLOO A University of Waterloo researcher is combining 3D printing and his expertise in nanomedicine to create a novel way to protect women from getting HIV.

Emmanuel Ho, an associate professor in UW's School of Pharmacy, is developing an intra-vaginal ring that would provide precise doses of medication that could stop HIV infection at the site of transmission.

"This will empower women to protect themselves," Ho said.

The ring is made of medical-grade plastic with hollow tubing and tiny pores. Medicine loaded into the ring, which is placed in the vagina, is slowly released and absorbed by the body.

Ho is testing a combination of anti-HIV and anti-inflammatory drugs. Inflammation in the vagina increases the risk of acquiring HIV because inflammation draws the immune cells that are infected by the virus.

"If a woman has high levels of inflammation in the genital tract, then the probability of HIV infection is much higher," said Ho's collaborator Keith Fowke, professor and head of Medical Microbiology and Infectious Diseases at the University of Manitoba.

Releasing anti-inflammation medication directly could reduce the risk, and then the anti-HIV medication could combat the virus if a woman is infected.

"It's kind of like a two-pronged approach," Ho said.

Intra-vaginal rings with a similar shape and design, such as NuvaRing, have been approved for birth control and hormone replacement therapy.

However, Ho said a 3D printed model allows for more precise design and drug delivery. It's also cheaper and avoids the waste from traditional manufacturing where melted polymers are poured into a mould.

Ho's ring could be used for a variety of medications, including hormonal contraceptives. Delivering it to the site would reduce the amount of medication needed, which would mean fewer side-effects.

Condoms and anti-HIV treatment are available to prevent HIV infection. But social and cultural factors can impede condom use, no to mention availability in developing countries, and oral medications need to be taken daily.

The ring would offer a discrete, effective and convenient approach.

"This would be a new option," Ho said.

The research recently got a grant from the Canadian government to move onto animal testing with the University of Manitoba and the Centers for Disease Control and Prevention in the United States, bringing it one step closer to reality from concept.

Globally, infection rates are on the rise for HIV the virus that causes AIDS and kills one million people globally each year, according to UNAIDS.

"There's a definite need," Ho said.

jweidner@therecord.com

Twitter: @WeidnerRecord

jweidner@therecord.com

Twitter: @WeidnerRecord

Read more from the original source:
3D printing and nanomedicine combined to combat HIV - TheRecord.com

Recommendation and review posted by Alexandra Lee Anderson

Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors – BioSpace

LOS ANGELES, Feb. 4, 2020 /PRNewswire/ --Immix Biopharma, Incannounced today that the first patient in the USA was dosed successfully in its flagship phase 1b/2a clinical trial testing Imx-110 in patients with refractory solid tumors.To-date, the trial has accrued patients across tumor types. The expansion of the study to the US builds upon Immix' results from Australia, wherein six cohorts were dosed with no treatment-related serious adverse events observed and dose escalation is continuing.

The first US patient was dosed at Sarcoma Oncology Research Center in Santa Monica, California - led by Dr. Sant Chawla, a world renowned expert in sarcoma treatment and clinical research. Based on his extensive experience with anthracycline-based experimental therapies for sarcoma, including CytRx' Aldoxorubicin, Dr. Chawla shared his optimism for Imx-110 as an investigational candidate both from the standpoint of superior efficacy and a lower risk of cardiac complications associated with older formulations of doxorubicin.Dr. Chawla's colleague, Dr. Erlinda Gordon is the Principal Investigator leading the study at Sarcoma Oncology Research Center in Santa Monica.

Dr. Gordon is a Diplomate of the American Board of Pediatric Hematology/Oncology and previously a Tenured Associate Professor for 24 years at USC and currently a Professor Emeritus at the USC Keck School of Medicine, Los Angeles, California. She is a co-inventor of more than 150 patents in biomedical research, and patented the first targeted gene delivery system for cancer in the USA, Europe and the Philippines. She has authored more than 100 original peer-reviewed articles and served as Editor-in-Chief of the International Journal of Pediatric Hematology-Oncology, Director of the Red Cell Defects Program and the NIH-funded Comprehensive Hemophilia Center at Children's Hospital of Los Angeles and the NIH-funded Children's Oncology Group. Dr. Gordon was co-founder of two biotechnology companies and is a pioneer in the development of targeted gene therapy products.

For more information on the Imx-110 study, please visit clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03382340.

Immix also has an open call for investigator initiated studies where the company will provide Imx-110 at no charge.

About Imx-110Imx-110 is a first-in-class combination therapy designed to inhibit cancer resistance and evolvability while inducing apoptosis. Imx-110 contains NF-kB/Stat3/pan-kinase inhibitor curcumin combined with a small amount of doxorubicin encased in a nano-sized delivery system for optimal tumor penetration. The nanoparticle is tunable in that it can be bound to various targeting moieties, allowing it to deliver even more payload to tumors or other cell populations of interest, if needed. Imx-110 showed preclinical efficacy in glioblastoma, multiple myeloma, triple-negative breast, colorectal, ovarian, and pancreatic tumor models with the mechanism of action being a 5x increase in cancer cell apoptosis compared to doxorubicin alone, and a wholesale shift in the tumor microenvironment post administration.

About the CompanyImmix Biopharma, Inc. is a privately-held, biopharmaceutical firm focused on developing safe and effective therapies for cancer patients. The company was founded by Vladimir Torchilin, Ph.D., D.Sc., Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University; physician-scientist and clinical researcher Ilya Rachman, MD, PhD, MBA; and Sean D. Senn, JD, MSc., MBA, a senior biotechnology patent attorney. Immix's founding investor is a family office focused on harnessing scientific advances in order to engineer transformative and effective cancer treatments. For more information visit http://www.immixbio.com.

Media ContactRyan Witt+1 (888) 958-1084info@immixbio.com

View original content:http://www.prnewswire.com/news-releases/immix-doses-first-patient-in-usa-in-its-phase-1b2a-trial-in-patients-with-advanced-solid-tumors-300998208.html

SOURCE Immix Biopharma, Inc.

Read the original here:
Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors - BioSpace

Recommendation and review posted by Alexandra Lee Anderson

These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus – Yahoo Finance

With the outbreak of the Wuhan coronavirus in China and the increasing death toll, there is little doubt that global financial markets are going to be impacted negatively. As Trump considers banning all flights to China, airline and travel companies like United Airlines (NASDAQ:UAL), Expedia (NASDAQ:EXPE), American Airlines (NASDAQ:AAL) and many more have seen their stock prices crash. There is a strong negative sentiment on the Chinese economy as a whole as the virus has shaken up many of the erstwhile strong sectors.

Overview of the virus

For those readers who are not aware, the Wuhan coronavirus first emerged in the central Chinese city of the same name through the meat and seafood markets and has spread across the country with over a thousand cases and more than a hundred deaths confirmed. It belongs to the same family of viruses as SARS (severe acute respiratory syndrome) and the MERS (Middle East respiratory syndrome). This group of crown-shaped viruses can become deadly if it causes the patient to develop lower respiratory tract illnesses such as pneumonia or bronchitis. It is highly contagious in nature, spreading through the slightest form of saliva contact, whether it is coughing or kissing. The story of the Wuhan coronavirus sounds like history repeating itself after SARS shook up global markets in 2002-03.

It is worth recalling that pharma and biotech companies catering to the respiratory system and providing anti-viral medications were the ones that appreciated the most during the time of SARS, and the current situation does not appear very different. With a strong negative sentiment prevailing in most other sectors, pharma and biotech are perhaps the only sectors that could get a boost from a new bullish sentiment resulting from this virus. Based on the nature of the virus and the expected treatments, the following four stocks could benefit hugely given their presence in the field of anti-viral respiratory medication.

GlaxoSmithKline plc

Since the Wuhan coronavirus belongs to the same family as the SARS, it is important to recall those companies which benefitted the most from the SARS outbreak. While SARS may not have a defined cure even today, the most commonly prescribed form of treatment is the same as that for pneumonia. GlaxoSmithKline plc (NYSE:GSK) is one of the leaders in the space of anti-viral treatments for respiratory disorders like pneumonia.

The above chart shows how the company's stock grew as much as 35% during the SARS phase, which is quite significant for its size. It is worth highlighting that GlaxoSmithKline is a global player with its biggest markets being the U.S. and the UK. Respiratory oral health is one of its strongest segments, and it has a monopolistic position in many anti-viral medications. For example, its Shingrix vaccine for shingles is the only preventive vaccine for the disease across the globe. It has also performed strong research on HIV. The stock has appreciated by over 20% in the past twelve months and also provided a dividend yield of 4.32%, making it an excellent bet for investors.

Abbott Laboratories

Abbott Laboratories (NYSE:ABT) is more of a play on the diagnostics aspect rather than the treatment aspect of the Wuhan virus. The company is one of the largest global biotech giants, and one of its most important offerings relevant to the Wuhan virus situation is its diagnostic capabilities. Abbott is known to provide rapid diagnostics systems for infectious diseases along with remote patient monitoring, informatics and automation solutions that are all very relevant to diagnose the Wuhan virus victims. It also has molecular point-of-care testing for HIV, influenza A and B and RSV.

Story continues

Abbott's relevance was so strong in the SARS era that it appreciated by over 30% in those times and is already up by around 22% in the past 12 months. Given the current situation, the upward momentum of the stock might continue for a while.

Gilead Sciences, Inc.

Biotech giant Gilead Sciences, Inc. (NASDAQ:GILD) was easily one of the biggest beneficiaries in the SARS outbreak, as it saw its stock appreciate more than 200% throughout the outbreak.

The reason for this appreciation is that Gilead gets most of its revenues from the anti-viral segment. The company's stock price has been stable throughout economic downturns and it is not without reason that the company has a 4.5-star business predictability rating on Gurufocus. Not only is it debt-free, it is known to distribute a good amount of dividend (current yield of 3.93%) to shareholders over and above capital appreciation. Not only has it done remarkable research on HIV, Gilead also has some very well known anti-viral brands in the market such as Atripla, Cayston, Sovaldi, Odefsey, Truvada, Biktarvy and so on. It is certainly going to be moving fast in the race to provide strong anti-viral treatments for the Wuhan coronavirus.

NanoViricides, Inc.

NanoViricides, Inc. (NNVC) is the only small, development-stage company on this list, but it is here for a reason. Since the news of the Wuhan virus outbreak, NanoViricides has seen its stock shoot up by as much as 349%.

The company, led by biotech veteran Dr. Anil Diwan, specializes in anti-viral research and had actively worked on MERS in the past. Its current research is also focused on treating viruses through its proprietary nanomedicine technology, where it uses anti-viral nanomachines known as "nanoviricides." The company has a decent pipeline of anti-viral drug candidates catering to diseases such as shingles, herpes, seasonal and potentially-epidemic influenzas, bird flu, HIV, cold sores, viral eye diseases and dengue viruses.

In fact, its most rapidly advancing drug candidate is a topical cream for the treatment of shingles, which is now advancing to the stage of IND application before progressing to human trials. While the company may not have significant revenues today, it hopes to start monetizing the progress of this cream through licensing agreements after the initial phases of the human trials. It has been one of the biggest beneficiaries of the Wuhan virus outbreak so far in terms of stock appreciation, and the upward momentum is expected to remain strong with the IND application results arriving soon.

Conclusion

The Wuhan coronavirus may have a huge negative impact on global markets over a span of time, but the pharma and biotech space is one where it presents a good opportunity. As its fears grip the world, companies like the ones mentioned above are working hard to capitalize on this opportunity and maximize their revenues. In such a situation, it is often beneficial for investors to be opportunistic and make the most returns through investing in these companies.

Disclosure: No positions.

Read more here:

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.

Read this article:
These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus - Yahoo Finance

Recommendation and review posted by Alexandra Lee Anderson

Why China Is The Future of Nanoscience – OZY

Everything about Chinas drive to become a leading innovator works on a giant scale. Ambitions are enormous, budgets are vast and the focus is widespread. And in many fields, its beginning to close the gap with U.S. and European institutions. But its in the study of materials on the scale of a billionth of a meter nanoscience that China is already fast overtaking its international rivals.

From cloning to cancer research, China is using nanoscience and nanotechnology innovation to drive some of the worlds biggest breakthroughs. In July, an international team of researchers led by Chinese scientists developed a new form of synthetic, biodegradable nanoparticle. Capable of targeting, penetrating and altering cells by delivering the CRISPR/Cas9 gene-editing tool into a cell, the nanoparticle can be used in the treatment of some single-gene disorders, as well as other diseases including some forms of cancer.

In a separate project, scientists at Chinas Nanjing University haveused nanoparticles to target and destroy abnormal proteins known to causebreast cancer. Tests in mice showed the treatment reduced the size of tumors byhalf compared to the control group. At the University of Science and Technologyof China, a team of researchers claims to have given mice infrared night visionby injecting nanoparticles into their eyes.

And at the State Key Laboratory of Robotics in the northeast city of Shenyang, researchers have developed a laser that produces a tiny gas bubble. This bubble can be used as a tiny robot to manipulate and move materials on a nanoscale with microscopic precision. The technology promises new possibilities in the field of artificial tissue creation and cloning.These innovations are backed up by a scale of research thats unmatched. In 2018, Chinese researchers were on their own responsible for 40 percent of all global scientific papers in the field, with the U.S. (15 percent) a distant second.

Nanotechnology supports biomedicine and quantum technology development and makes its way into everyday life through advancements in consumer electronics and artificial intelligence, all areas where China seeks global dominance. Being at the forefront of cutting-edge nano research greatly improves Chinas prospects for success, especially in biomedicine, where it has long trailed rivals.

Drug delivery, nanomedicine and tissue engineering are rapidly growing fields that rely on our ability to engineernanoparticles and biomaterialstargeted at specific cells, such as cancer cells,to enhance the therapeutic efficacy, says Dr. Omid Kavehei, deputy director of the University of Sydney Nano Institute.

Chinas gains could help it win critical patents in advanced research in fields like cancer, where the U.S. has historically led.

Strong state support in nanoscience as in tech fields such as artificial intelligence and robotics is also a key advantage for China, Bai Chunli, president of the Chinese Academy of Sciences (CAS), conceded publicly in August. The importance the government places on competitiveness in the field is underlined by its inclusion as a strategic industry in Chinas 13th Five-Year Plan, ensuring state funding and legislative and regulatory support. Nanotech research is also a key component of the ambitious Made in China 2025 initiative aimed at turning China into a high-tech manufacturing powerhouse.

Thats allowing China to find success in myriad areas of nanotechnology. A new nanomaterial invented by CAS scientists promises to eliminate millions of metric tons of liquid pollution and emissions from organic chemicals used in printing plates and ink. It is one of the headline acts for CAS as it drives to apply nanotechnology innovation to the development of consumer tech. So far, the project has landed $780 million in investment.

China still relies on collaborations with foreign institutions in most of the subfields of nanoscience and nanotechnology.

Shengfu Yang, University of Leicester

In an October 2019 paper published by science journalNano Energy, Dalian Institute of Chemical Physics announced the creation of a tiny lithium battery that is resilient to low temperatures, capable of operating at 80 percent efficiency at temperatures of -40 degrees Celsius. While the battery presents huge potential for industries from electric cars to mobile devices, the ability of the battery to operate at extreme temperatures is particularly important to the future of space technology.

Industry experts point to the return of foreign-trained Chinese researchers to the Middle Kingdom, lured by the promise of readily available funding, as an important factor of Chinas progress. The next step is for China to become self-sufficient in developing talent. Currently China still relies on collaborations with foreign institutions in most of the subfields of nanoscience and nanotechnology, says Shengfu Yang, nanochemistry professor at the University of Leicester. The nanoparticle that delivers the gene-editing tool into cells was developed in partnership with scientists at Tufts University in the United States, for instance.

Enhancing innovation in the private sector will also help China kick on, says Zheng Xiao Guo, professor of chemistry and mechanical engineering at the University of Hong Kong. State-funded institutions have played a far bigger role in nanotechnology innovations, and private institutions or enterprises in this area are not as strong, he says.

But the number of private companies driving nanotech product innovation is rapidly growing, Zheng concedes. Nanopolis, the worlds largest nanotech industrial zone, located in the eastern city of Suzhou, houses several private multinationals and new Chinese startups across nanotech fields. China now also leads the globe in newly established nanotech companies. In 2018, Tencent founder Ma Huateng joined a number of high-profile businesspeople in financing the establishment ofChinas first private research institute,Westlake University, with nanotech a main focus for research.

Private-sector involvement opens new and unique pools of funding and talent, and the focus is on applicable research even in a country like China, where state-sponsored institutions still dominate, say experts.

That combination of a growing talent pool and a state-sponsored desire to become a global leader, with an expanding private-sector ecosystem, will be hard for other countries to match. Chinas big leap in small science is just starting.

Link:
Why China Is The Future of Nanoscience - OZY

Recommendation and review posted by Alexandra Lee Anderson

NanoViricides: A History Of Producing Headlines Without Producing A Product – Seeking Alpha

The Wuhan Coronavirus has rapidly become a global health crisis and is producing hourly headlines. As a result, many of the vaccine tickers started to experience parabolic reactions as investors speculate on who will benefit from the growing health crisis. NanoViricides (NNVC) is one of these tickers and has rocketed from ~$3 to around $19 per share. On January 30th, NanoViricides announced it is has already initiated a program for developing a treatment for the 2019-nCOV." In addition, the company believes that their platform technology allows them to possibly have the most rapid pathway for new drug development against viral diseases. This triggered a sharp spike in the share price and has investors keeping a close eye on NNVC for their next move. Unfortunately, the company has yet to gain support from governmental and international agencies, so it doesnt appear NanoViricides is going to be in lead considering Moderna (MRNA) at least has a clinical collaboration with NIH. What is more, the company has started several pipeline programs but has yet to put one into human trials. Consequently, I believe investors need to be cautious around this ticker and should be skeptical about its ability to be a long-term investment.

I intend to provide a brief background on the companys platform technology and pipeline programs. In addition, I discuss my concerns around the companys technology and the ability to get one of their programs through the FDA. Moreover, I recap the companys history of publicizing their intention to develop a therapy for the latest outbreak but has yet to get one of these programs into the clinic.

NanoViricides is committed to the advancement of nanomedicine drugs in the battle against viruses. The companys nanoviricide platform technology intends to develop first-in-class drugs to envelope virus particles, which should block a virus from infecting a healthy cell and will eventually destroy the virus.

Figure 1: NanoViricide Mechanism of Action (Source: NNVC)

NanoViricides has its own c-GMP capable manufacturing facility that can be used to produce their own product candidates for both clinical and commercial use. In terms of pipeline programs, the company has multiple preclinical programs that are moving closer to an IND and into human trials (Figure 2).

Figure 2: NanoViricide Pipeline (Source: NNVC)

At the moment, the company is focused on bringing their NV-HHV-101 HerpeCide program into human trials. This would be the companys lead product candidate for a topical treatment for shingles rash and would be the companys first clinical program. According to the company, NV-HHV-101 had positive GLP Safety/Toxicology and non-GLP studies. Unfortunately, the company hasnt been able to produce any animal models in order to evaluate their dermal treatment but has been using ex vivo human skin organ culture model studies to determine some safety and efficacy. NanoViricides is preparing to file an IND and transition into a clinical-stage biotech.

Once NV-HHV-101 is in the clinic, the company expects to advance their HSV-1 cold sores and of HSV-2 genital ulcers programs. In addition, the company has several preclinical programs that include therapies for HIV, Dengue, Ebola, Bird Flu. These programs are at different stages of preclinical development and have demonstrated safety in animal models. According to the company, their anti-HIV drug candidate has demonstrated complete suppression of the HIV virus in mouse models, which would lead to a functional cure.

My Concerns

Does the NanoViricide entice or attack a virus? After reading through the companys presentation, I couldnt come to a conclusion about how their platform works. The company has illustrated that their NanoViricides attacks and envelopes the virus (Figure 1). However, they have also stated that the NanoViricides fools the virus that it is a host cell and then entraps the virus. Perhaps the NanoViricides work both ways, but it still has me wondering about how it is supposed to act inside the bodya human host cell is astronomically bigger than the virus that is attempting to infect it (Figure 3).

Figure 3: Size Comparisons (Source: Research Gate)

Viruses are measured in nanometers and human cells are measured in microns, yet, the NanoViricide is attempting to trick the virus to thinking it is human cell. Indeed, a virus doesnt decide to attach to a human cell because of its size but rather surface receptors. Still, I dont see it as it being tricked but rather just getting stuck and consumed...which makes me wonder about the size of a NanoViricide...How big of a virus can it cover? Can multiple NanoViricides work on one virus?

How does the NanoViricide destroy the virus? Viruses are quite resilient for just being RNA or DNA encapsulated in a protein coat. A virus requires host cells to carry out the remaining life processes in order to reproduce. This gives our bodies a chance to identify and destroy viruses with our innate and adaptive immune systems by several complex mechanisms. So, an explanation of how a NanoViricide destroys a virus needs to go beyond it encapsulates and destroys. The company explains that the NanoViricide delivers a devastating payload of active pharmaceutical ingredients API into the virus particle, thereby completely destroying the enemy. What is this API? Does it cause cytotoxicity? Is it relying opsonization? The company has a slide (Figure 4), that shows NanoVircide dismantling the capsid.

Figure 4: NanoViricide Dismantling (Source: NNVC)

Admittedly, the company is attempting to be one of the leaders in nanomedicine, so perhaps the mechanisms are beyond me and contemporary medicine. Unfortunately, we cant rely on currently approved products or science to understand how NanoViricide works, which doesnt bode well in my opinion. Contemporary vaccines, antibodies, and anti-viral drugs are effective against viruses, so I have to imagine health agencies and organizations are going to side with the standard-of-care modalities rather than take a chance with unproven technology.

Another issue I have with their technology is how they plan to run clinical trials for some of their pipeline programs. Take their shingles cream candidate, which is intended to be a topical treatment for the shingles rash. How is the company supposed to run a clinical trial for this? What would be an inclusion or exclusion trial for this? How would they know if it is better at clearing up a rash vs. placebo alone? A shingles rash appears abruptly and can last several weeks, so, determining if NanoViricides were able to shorten or diminish the impact of the rash would be difficult to measure. I have the same issue with infectious viruses, where the company is attempting to prove their NanoViricides work against a dangerous virus. With vaccines, companies are able to determine their ability to stimulate the immune system and elicit some seroprotection without the subject being infected with the virus. NanoViricides is not a vaccine, so the subject would have to be infected with the Wuhan Coronavirus in order to determine if it is effective against the virus. Overall, I see the company having a hard time clearing some of these regulatory hurdles and being able to prove its product works the way it is intended.

The other concerning issue is the companys history of developing the current global health crisis and has yet to get that program into the clinic. The company started to develop an Avian Bird Flu drug back in 2006, and yet, it has yet to hit the clinic. The same can be said for their Dengue program that was started in 2007, and the same with Ebola in 2008 and 2014. In addition, the company promoted their efforts against MERS in 2014 and has been attempting an HIV program for several years. Unfortunately, none of these programs have made it into the clinic for human trials but investors cash has made it into the companys bank account. It appears the company takes advantage of any major global health crisis by claiming they have a potential product and they are working hard to quickly progress their NanoViricides against the most recent headline virus. In reality, the company doesnt move out of discovery and preclinical studies. Sadly, investors have been enticed by the prospects of investing in a company that has an answer to the current scare, only to experience dilution that has devastated the share price over the years (Figure 5).

Figure 5: NNVC Weekly Chart (Source: Trendspider)

Even if the company wanted to push forward with development and start human trials, it will need a large amount of cash to get the ball rolling. What is more, the company would most likely need to secure commercial partners to produce and distribute their products. Admittedly, the company just raised about $7.5M in a public offering after the stock popped once the Wuhan virus started to catch the publics eye. Still, the company will most likely need some additional funding to get one of their product candidates through the FDA.

NanoViricide might be working on a potential treatment for the Wuhan Coronavirus, but investors need to be cautious here. The company has a 15-year history of promoting their attempts to develop a leading therapy for the latest virus but has yet to get one of these programs into human trials. Even if the company is able to develop a potential candidate, it is going to need the help from government agencies and institutions to be used and it looks as if some of the worlds biggest pharmaceutical and biotechs are already starting to send some of their anti-viral products to China to help with the outbreak. In fact, Johnson & Johnson (JNJ) is already working on a vaccine and has donated some of their HIV medications. What is more, NanoViricides is not even listed on a CNBC list of companies working on a Coronavirus vaccine or drug (Figure 6).

Figure 6: List of Coronavirus Companies (Source: CNBC)

Considering these points, I would advise investors to wary of investing until the company is able to get an IND and reports their first human data. Until then, I expect shorts to start piling on once the market realizes the company is reusing its old playbook of promoting a program and never following through with it.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Link:
NanoViricides: A History Of Producing Headlines Without Producing A Product - Seeking Alpha

Recommendation and review posted by Alexandra Lee Anderson

Nanomedicine Market: Industry Analysis and forecast 2026 – Expedition 99

Nanomedicine Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.

Nanomedicine Market Drivers and Restrains:Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.

The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/39223

Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.

Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/39223

Scope of the Nanomedicine Market:

by Modality:

Diagnostics Treatmentsby Diseases:

Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological Diseases

by Application:

Neurology Cardiovascular Anti-Inflammatory Anti-Infectives Oncology

by Region:

Asia Pacific North America Europe Latin America Middle East Africa

Major Players:

Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.

Browse Full Report with Facts and Figures of Nanomedicine Market Report at:https://www.maximizemarketresearch.com/market-report/nanomedicine-market/39223/

MAJOR TOC OF THE REPORT

Chapter One: Nanomedicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanomedicine Market Competition, by Players

Chapter Four: Global Nanomedicine Market Size by Regions

Chapter Five: North America Nanomedicine Revenue by Countries

Chapter Six: Europe Nanomedicine Revenue by Countries

Chapter Seven: Asia-Pacific Nanomedicine Revenue by Countries

Chapter Eight: South America Nanomedicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanomedicine by Countries

Chapter Ten: Global Nanomedicine Market Segment by Type

Chapter Eleven: Global Nanomedicine Market Segment by Application

Chapter Twelve: Global Nanomedicine Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

The rest is here:
Nanomedicine Market: Industry Analysis and forecast 2026 - Expedition 99

Recommendation and review posted by Alexandra Lee Anderson

Healthcare Nanotechnology Nanomedicine Market : Outlook Continues to Remain Positive by 2015 2021 – The Trusted Chronicle

Nanotechnology is one of the most promising technologies in 21st century. Nanotechnology is a term used when technological developments occur at 0.1 to 100 nm scale. Nano medicine is a branch of nanotechnology which involves medicine development at molecular scale for diagnosis, prevention, treatment of diseases and even regeneration of tissues and organs.

Thus it helps to preserve and improve human health. Nanomedicine offers an impressive solution for various life threatening diseases such as cancer, Parkinson, Alzheimer, diabetes, orthopedic problems, diseases related to blood, lungs, neurological, and cardiovascular system.

Development of a new nenomedicine takes several years which are based on various technologies such as dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.

In the field of diagnosis, nanotechnology based methods are more precise, reliable and require minimum amount of biological sample which avoid considerable reduction in consumption of reagents and disposables.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/6370

Apart from diagnosis, nanotechnology is more widely used in drug delivery purpose due to nanoscale particles with larger surface to volume ratio than micro and macro size particle responsible for higher drug loading. Nano size products allow to enter into body cavities for diagnosis or treatment with minimum invasiveness and increased bioavailability. This will not only improve the efficacy of treatment and diagnosis, but also reduces the side effects of drugs in case of targeted therapy.

Globalnanomedicinemarket is majorly segmented on the basis of applications in medicines, targeted disease and geography. Applications segment includes drug delivery (carrier), drugs, biomaterials, active implant, in-vitro diagnostic, and in-vivo imaging. Global nanomedicine divided on the basis of targeted diseases or disorders in following segment: neurology, cardiovascular, oncology, anti-inflammatory, anti-infective and others.

Geographically, nanomedicine market is classified into North America, Europe, Asia Pacific, Latin America, and MEA. Considering nanomedicine market by application, drug delivery contribute higher followed by in-vitro diagnostics. Global nanomedicine market was dominated by oncology segment in 2012 due to ability of nanomedicine to cross body barriers and targeted to tumors specifically however cardiovascular nanomedicine market is fastest growing segment. Geographically, North America dominated the market in 2013 and is expected to maintain its position in the near future.

Request Customization of this Report @https://www.persistencemarketresearch.com/request-customization/6370

Asia Pacific market is anticipated to grow at faster rate due to rapid increase in geriatric population and rising awareness regarding health care. Europe is expected to grow at faster rate than North America due to extensive product pipeline portfolio and constantly improving regulatory framework.

Major drivers for nanomedicine market include improved regulatory framework, increasing technological know-how and research funding, rising government support and continuous increase in the prevalence of chronic diseases such as obesity, diabetes, cancer, kidney disorder, and orthopedic diseases. Some other driving factors include rising number of geriatric population, awareness of nanomedicine application and presence of high unmet medical needs. Growing demand of nanomedicines from the end users is expected to drive the market in the forecast period.

However, market entry of new companies is expected to bridge the gap between supply and demand of nanomedicines. Above mentioned drivers currently outweigh the risk associated with nanomedicines such as toxicity and high cost. At present, cancer is one of the major targeted areas in which nanomedicines have made contribution. Doxil, Depocyt, Abraxane, Oncospar, and Neulasta are some of the examples of pharmaceuticals formulated using nanotechnology.

For In-depth Competitive Analysis, Pre-Book Report Now @https://www.persistencemarketresearch.com/checkout/6370

Market Players

Key players in the global nanomedicine market include:

Go here to see the original:
Healthcare Nanotechnology Nanomedicine Market : Outlook Continues to Remain Positive by 2015 2021 - The Trusted Chronicle

Recommendation and review posted by Alexandra Lee Anderson

Cape Breton University researchers hope to help water woes – SaltWire Network

SYDNEY, N.S.

Work taking place at Cape Breton University could help small communities both locally and globally deal with water contamination issues.

Shine (Xu) Zhang is a CBU chemistry professor and holds the Tier II Canada Research Chair in healthy environments and communities and the industrial research chair in applied nanotechnology. He is working on a project that involves electrochemical water treatment which he believes can offer a green, efficient and cost-effective alternative.

Water pollution, water contamination is a global concern but its also a local problem for Cape Breton and Nova Scotia, Zhang said.

He said he wanted to take on water contamination as a research topic because it is such a big issue.

CBU is a local university, but CBU really wants to contribute to the community, Zhang said. The environment is a big issue. Water contamination is also a global issue, therefore, research here, if we do a good job, can not only help local communities but also help people far away from here.

We want to apply what we learn to solve some real-world problems.

His research program aims at exploiting nanotechnology and nanomaterials for environmental and health applications with a focus on water treatment, cancer diagnostics and treatment with precision nanomedicine. Zhang has published 65 journal articles.

He describes the technology hes developed as being relatively simple, with an electrode acting like a filter. One electrode removed organic material while another electrode removed heavy metals.

Water comes through the filter, dirty water becomes clean, Zhang said.

The technology, I feel is useful because, from a research standpoint, energy consumption is very low, so essentially its quite cost-effective. That is compatible, for example, with solar panel, those kinds of various sustainable power source. It can be a very automatic system, so you dont need a lot of manpower to run it.

A request for proposals for a market research consultant issued by CBU recently closed and Zhangs team is currently reviewing the proposals received. It asked for proposals to outline how the consultant would go about understanding and marketing the technology, from lab to market through the successful negotiation of a licence.

Zhang said they are now evaluating the best way to commercialize the technology.

Were looking for different industry partners so that we can do further development of specific products or applications for this to meet different needs, he said. For example, we work with environmental remediation companies, we work with landfill leachate, we work on pharmaceutical wastewater. We want to find industry partners to work on further development.

Its hoped the consultant that they hire will assist in finding those partners. A prototype has been developed.

The ideal starting industry level would be 3,000 litres a day, were about halfway there already, were at about 1,500 litres a day," said Andrew Carrier, who works closely with Zhang.

Carrier noted the technology also works in flows, so you dont need a large quantity of contaminated water to make use of it, and it doesnt take up much physical space. They want the technology to be accessible to as many people who can make use of it as possible, he added.

Its easy to put into a remote location without having to invest much capital, Carrier said.

Zhang noted the technology also doesnt generate any sort of secondary waste as a result of its water treatment.

Zhangs work has been supported by the Atlantic Canada Opportunities Agency, Innovacorp, Springboard Innovation Mobilization program, Nova Scotia Lands as well as CBU.

RELATED:

Read the original post:
Cape Breton University researchers hope to help water woes - SaltWire Network

Recommendation and review posted by Alexandra Lee Anderson

Healthcare Nanotechnology (Nanomedicine) Market Share, Size, Future Demand, Global Research, Top Leading Player, Emerging Trends and Forecast to 2015 …

In 2018, the market size of Casing Heads Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Casing Heads .

This report studies the global market size of Casing Heads , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2566962&source=atm

This study presents the Casing Heads Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Casing Heads history breakdown data from 2014 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2018.

In global Casing Heads market, the following companies are covered:

TechnipFMCJMP Petroleum TechnologiesDelta CorporationGE Oil & GasIntegrated EquipmentWellhead Systems Incorporated (WSI)TIGER VALVE COMPANYHorizon WellheadWorldwide Oilfield Machine (WOM)Larkin ProductsIAL ENGINEERING SERVICES

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeMonolithic TypeCombined Type

Segment by ApplicationOil/Gas WellsOther

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2566962&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Casing Heads product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Casing Heads , with price, sales, revenue and global market share of Casing Heads in 2017 and 2018.

Chapter 3, the Casing Heads competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Casing Heads breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2018.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2566962&licType=S&source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2018.

Chapter 12, Casing Heads market forecast, by regions, type and application, with sales and revenue, from 2018 to 2024.

Chapter 13, 14 and 15, to describe Casing Heads sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Link:
Healthcare Nanotechnology (Nanomedicine) Market Share, Size, Future Demand, Global Research, Top Leading Player, Emerging Trends and Forecast to 2015 ...

Recommendation and review posted by Alexandra Lee Anderson


Page 20«..10..19202122..3040..»